24/7 Market News Snapshot 22 October, 2025 – CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC)

October 22, 2025

DENVER, Colo., 22 October, 2025 (www.247marketnews.com) – (NASDAQ:GDTC) are discussed in this article.
CytoMed Therapeutics Limited is currently seeing fluctuations in its stock performance, opening at $2.87 and trading down to approximately $2.455, reflecting a decline of about 4.47% from the previous session’s close at $2.57. The trading volume today has reached around 1.27 million shares, suggesting a notable shift in investor sentiment. Observations of the stock’s short-term trends reveal a bearish pattern, with resistance levels identified at $2.57 and potential support located near $2.40. Investors are advised to pay close attention to moving averages and trading volumes to gauge future price movements, remaining vigilant for reversal signals before executing larger trades.

In a strategic move to strengthen its shareholder base, CytoMed has announced that Mr. Peter Choo, Executive Chairman and significant shareholder, has increased his stake in the Company. Mr. Choo purchased an additional 105,824 shares in open-market transactions, escalating his holdings to a total of 2.50% of the Company’s shares. With a newly adjusted total ownership of 21.95%, amounting to 2,388,246 shares, his commitment underscores his confidence in CytoMed’s mission to deliver affordable treatments for various cancers, including hematological and solid tumors.

Mr. Choo articulated his belief in the Company’s proprietary technologies designed to provide cost-effective and accessible immunotherapies for cancer treatment. He highlighted the growing investor interest in biotherapeutics, particularly within the Asian markets, as an encouraging factor for CytoMed’s ongoing innovations within the healthcare ecosystem. Established in 2018, CytoMed continues to focus on developing novel cell-based allogeneic immunotherapies, addressing the current limitations faced by CAR-T therapies in treating solid tumors. As the firm navigates these developments, it remains committed to transparency and will provide updated communications regarding any significant changes in shareholder investments.

Related news for (GDTC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.